secwatch.observer — SEC 8-K summary
======================================

Issuer:     Transcode Therapeutics, Inc. (RNAZ)
CIK:        0001829635
Form:       8-K/A
Filed at:   2026-05-26T10:43:50+00:00
Accession:  0001104659-26-065959
Event type: regulatory
Sentiment:  negative
Materiality: 0.80
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

TransCode Therapeutics receives Nasdaq deficiency notice for low stockholders' equity
--------------------------------------------------------------------------------

- Stockholders' equity reported at $1.25M as of March 31, 2026, below Nasdaq's $2.5M minimum.
- Company has 45 days (until July 3, 2026) to submit a plan to regain compliance.
- Plan hinges on stockholder approval to convert Series A Preferred Stock into common equity.
- If plan is rejected or compliance not regained within extension, Nasdaq may delist RNAZ.
- Failure to obtain approval by Dec 31, 2026 could trigger redemption of Series A Preferred at fair value.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829635/000110465926065959/0001104659-26-065959-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829635/000110465926065959/tm2615597d1_8ka.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-065959

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer